# HIF1α reinforces PPARγ-dependent metabolic rechanneling to support lipid accumulation in adipocytes

**Authors:** Chaonan Zhu, Meiqian Wu, Minh Duc Pham, Yue Wang, Arka Provo Das, Yijie Mao, Peter Mirtschink, Ting Yuan, Jaya Krishnan

PMC · DOI: 10.3389/fmmed.2026.1716464 · Frontiers in Molecular Medicine · 2026-02-23

## TL;DR

This study shows how HIF1α helps fat cells store more lipids by working with PPARγ, leading to bigger fat cells and metabolic issues during obesity.

## Contribution

The study reveals a new role for HIF1α in promoting lipid accumulation in mature adipocytes through PPARγ-dependent pathways.

## Key findings

- Deleting HIF1α in fat cells reduced adipose mass and improved glucose tolerance and insulin sensitivity.
- HIF1α enhances PPARγ-dependent lipid synthesis by linking glycolysis to triacylglyceride production.
- The GPD1–GPAT axis is identified as a key driver of lipid accumulation in fat cells.

## Abstract

Adipose tissue hypoxia is a hallmark of obesity and partly contributes to metabolic dysfunction through effects on differentiated adipocytes. Although hypoxia-inducible factor 1α (HIF1α) is a key transcriptional mediator of hypoxic responses, its state-dependent metabolic role remains incompletely defined in mature adipocytes. Herein, we investigate how HIF1α regulates lipid metabolism in differentiated adipocytes under nutrient excess conditions.

An adipocyte-specific Hif1α knockout mouse model was subjected to high-fat diet feeding in vivo. Adipose mass, adipocyte size, glucose tolerance, and insulin sensitivity were assessed. Metabolic and enzymatic analyses focused on lipid anabolic pathways, including glycolysis-linked glycerolipid biosynthesis and PPARγ-dependent programs.

Adipocyte-specific deletion of Hif1α attenuated adipocyte hypertrophy, resulting in reduced adipose mass as well as improved systemic glucose tolerance and insulin sensitivity during high-fat diet feeding. Mechanistically, HIF1α reinforced PPARγ-dependent lipid anabolic programs by coordinating glycolytic flux with glycerolipid biosynthesis to promote the rechanneling of glucose-derived intermediates into triacylglyceride synthesis.

Together, these findings provide metabolic and enzymatic validations of a late-stage, state-dependent HIF1α–PPARγ lipid storage program and implicate the glycerol-3-phosphate dehydrogenase 1 (GPD1)–glycerol-3-phosphate acyltransferase (GPAT) axis as a key molecular executor of hypertrophic lipid accumulation in differentiated adipocytes.

## Linked entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468], GPD1 (glycerol-3-phosphate dehydrogenase 1) [NCBI Gene 2819], PPAT (phosphoribosyl pyrophosphate amidotransferase) [NCBI Gene 5471]
- **Diseases:** obesity (MONDO:0011122)

## Full-text entities

- **Genes:** Tpi1 (triosephosphate isomerase 1) [NCBI Gene 21991] {aka TIM, Tpi, Tpi-1}, Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, Ldha (lactate dehydrogenase A) [NCBI Gene 16828] {aka Ldh1, Ldhm, l7R2}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Ackr1 (atypical chemokine receptor 1 (Duffy blood group)) [NCBI Gene 13349] {aka CCBP1, CD234, Darc, Dfy, ESTM35, FY}, Gpd1 (glycerol-3-phosphate dehydrogenase 1 (soluble)) [NCBI Gene 14555] {aka GPD-C, GPDH-C, Gdc-1, Gdc1}, Fabp4 (fatty acid binding protein 4, adipocyte) [NCBI Gene 11770] {aka 422/aP2, AFABP, ALBP, ALBP/Ap2, Ap2, Lbpl}, Slc2a4 (solute carrier family 2 (facilitated glucose transporter), member 4) [NCBI Gene 20528] {aka GT2, Glut-4, Glut4, twgy}, Pdk1 (pyruvate dehydrogenase kinase, isoenzyme 1) [NCBI Gene 228026] {aka B830012B01, D530020C15Rik}, Slc2a1 (solute carrier family 2 (facilitated glucose transporter), member 1) [NCBI Gene 20525] {aka GT1, Glut-1, Glut1, M100200, Rgsc200}, Hif1a (hypoxia inducible factor 1, alpha subunit) [NCBI Gene 15251] {aka HIF-1-alpha, HIF1-alpha, HIF1alpha, MOP1, bHLHe78}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Gpam (glycerol-3-phosphate acyltransferase, mitochondrial) [NCBI Gene 14732] {aka GPAT, GPAT-1, GPAT1, P90}, HIF3A (hypoxia inducible factor 3 subunit alpha) [NCBI Gene 64344] {aka HIF-3A, HIF3-alpha-1, IPAS, MOP7, PASD7, bHLHe17}, EPAS1 (endothelial PAS domain protein 1) [NCBI Gene 2034] {aka ECYT4, HIF2A, HLF, MOP2, PASD2, bHLHe73}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, ARNT (aryl hydrocarbon receptor nuclear translocator) [NCBI Gene 405] {aka ARNT1, HIF-1-beta, HIF-1beta, HIF1-beta, HIF1B, HIF1BETA}
- **Diseases:** inflammation (MESH:D007249), metabolic disturbances (MESH:D024821), fibrosis (MESH:D005355), dyslipidemia (MESH:D050171), AD (MESH:D000544), Cancer (MESH:D009369), Defective glucose homeostasis (MESH:D044882), bodyweight gain (MESH:D015430), hypoxic (MESH:D002534), Obesity (MESH:D009765), metabolic diseases (MESH:D008659), Hypoxia (MESH:D000860), hypertension (MESH:D006973), cardiovascular disease (MESH:D002318), adipocyte hypertrophy (MESH:D006984), impaired insulin sensitivity (MESH:D007333), type 2 diabetes (MESH:D003924), adipose tissue dysfunction (MESH:D018205), cardiac hypertrophy (MESH:D006332), glucose intolerance (MESH:D018149)
- **Chemicals:** pyruvate (MESH:D019289), fat (MESH:D005223), phalloidin (MESH:D010590), oxygen (MESH:D010100), nitrogen (MESH:D009584), EDTA (MESH:D004492), Triton X-100 (MESH:D017830), Triacylglycerol (MESH:D014280), G3P (MESH:D005986), polyacrylamide (MESH:C016679), carbon (MESH:D002244), palmitoyl-CoA (MESH:D010171), glycerol-3-phosphate (MESH:C029620), FFAs (MESH:D005230), ORO (MESH:C011049), TRIzol (MESH:C411644), DTT (MESH:D004229), HCl (MESH:D006851), 5,5'-dithiobis(2-nitrobenzoic acid) (MESH:D004228), SDS (MESH:D012967), isopropanol (MESH:D019840), glycine (MESH:D005998), blood glucose (MESH:D001786), 14C1-glucose (-), fructose-1,6-bisphosphate (MESH:C029063), hexane (MESH:D006586), glycerol (MESH:D005990), carbohydrates (MESH:D002241), fatty acid (MESH:D005227), pimonidazole (MESH:C033815), lipid (MESH:D008055), paraformaldehyde (MESH:C003043), sodium carbonate (MESH:C005686), NAD+ (MESH:D009243), arsenate (MESH:C025657), DHAP (MESH:D004099), 4',6-diamidino-2-phenylindole (MESH:C007293), Glucose (MESH:D005947)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** NIH 3T3-L1 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0123), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968251/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12968251/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968251/full.md

---
Source: https://tomesphere.com/paper/PMC12968251